DRG Epidemiology’s coverage of narcolepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of narcolepsy for each country, as well as annualized case counts projected to the national population.
Most patient populations in the major mature pharmaceutical markets are forecast over a period of 20 years.
Prevalence of Narcolepsy per 100,000 Among People of All Ages in 2022 and 2042
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Narcolepsy Over the Next 20 Years
Epidemiology Data
Methods
Diagnosed Prevalence
Diagnosed Incidence
Reference Materials
Literature Review
Studies Included in the Analysis of Narcolepsy
Studies Excluded From the Analysis of Narcolepsy
Risk / Protective Factors
Risk / Protective Factors for Narcolepsy
Bibliography
Glossary
Abbreviations
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
